<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02256124</url>
  </required_header>
  <id_info>
    <org_study_id>MEC-2013-460</org_study_id>
    <secondary_id>2013-003405-26</secondary_id>
    <secondary_id>NL 44912.078.13</secondary_id>
    <secondary_id>113303003</secondary_id>
    <nct_id>NCT02256124</nct_id>
  </id_info>
  <brief_title>Effect of Lamotrigine on Cognition in NF1</brief_title>
  <acronym>NF1-EXCEL</acronym>
  <official_title>The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial (NF1-EXCEL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether lamotrigine can improve cognitive and
      neurophysiological deficits in adolescents with Neurofibromatosis type 1.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cognitive deficits in the autosomal dominant disorder Neurofibromatosis type 1 (NF1)
      typically consist of a lower than average IQ, impaired visual-spatial learning, attention
      problems and impaired executive functioning. These deficits have a substantial influence on
      the daily life of pediatric and adolescent individuals with NF1. One of the key underlying
      mechanisms of these deficits is an increased gamma-aminobutyric acid (GABA)-ergic inhibition
      and a subsequent decrease in synaptic plasticity. The ENCORE laboratory has recently shown
      that loss of the NF1-gene is associated with attenuated function of the
      hyperpolarization-activated cyclic nucleotide-gated channel 1 (HCN1). These channels,
      enriched in membranes of inhibitory interneurons, play an important role in the
      pathophysiology underlying the cognitive deficits in NF1. Lamotrigine, an HCN-agonist,
      restored function of HCN1, together with the electrophysiological and visual-spatial learning
      deficits in Nf1-mice. Thus, lamotrigine is a novel candidate drug for treating cognitive
      deficits associated with NF1.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Performance intelligence quotient (change from baseline)</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Assessed by the Wechsler Intelligence Scales for Children - third edition (WISC-III).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual-spatial working memory (change from baseline)</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Assessed by the Paired Associative Learning (PAL) task of the Cambridge Neuropsychological Test Automated Battery (CANTAB).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual perception (change from baseline)</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Assessed by the Motor Free Visual Perception Test - third edition (MVPT-3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained attention (change from baseline)</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Assessed by the Sustained Attention DOTS (SA-DOTS) of the Amsterdam Neuropsychological Tasks (ANT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual-motor integration (change from baseline)</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Assessed by the Beery-Buktenica Developmental Task of Visual Motor Integration - sixth edition (Beery-VMI-6).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fine motor coordination (change from baseline)</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Assessed by the Grooved Pegboard Test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attention problems (change from baseline)</measure>
    <time_frame>Baseline, 10 weeks, 26 weeks and 52 weeks</time_frame>
    <description>Assessed by a parent rated ADHD-questionnaire, the ADHD-vragenlijst (AVL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Executive functioning (change from baseline)</measure>
    <time_frame>Baseline, 26 weeks and 52 weeks</time_frame>
    <description>Assessed by the Behavior Rating Inventory for Executive Function parent questionnaire (BRIEF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short intracortical inhibition (SICI) (change from baseline)</measure>
    <time_frame>Baseline and 10 weeks</time_frame>
    <description>Assessed by paired pulse transcranial magnetic stimulation (ppTMS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term potentiation-like plasticity (change from baseline)</measure>
    <time_frame>Baseline and 10 weeks</time_frame>
    <description>Assessed by paired associative stimulation (PAS) using transcranial magnetic stimulation (TMS).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Full IQ (Intelligence Quotient)</measure>
    <time_frame>Baseline</time_frame>
    <description>Assessed by the Wechsler Intelligence Scales for children - third edition (WISC-III).</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse event registration</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks, 10 weeks, 14 weeks, 18 weeks, 26 weeks, 28 weeks and additionally on indication</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>NF1 disease severity</measure>
    <time_frame>Baseline</time_frame>
    <description>Assessed by the Riccardi scale.</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>Baseline, 10 weeks and 26 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetics: Area under the curve (AUC) and average steady state concentration.</measure>
    <time_frame>10 weeks, 18 weeks and 26 weeks</time_frame>
    <description>Pharmacokinetic model build with NONMEM analysis of trough level, Tmax level and a level 6 hours post-dose.</description>
  </other_outcome>
  <other_outcome>
    <measure>Kidney function</measure>
    <time_frame>Baseline and 10 weeks</time_frame>
    <description>Urea, creatinine</description>
  </other_outcome>
  <other_outcome>
    <measure>Hepatic enzymes</measure>
    <time_frame>Baseline and 10 weeks</time_frame>
    <description>ALAT, ASAT, GGT</description>
  </other_outcome>
  <other_outcome>
    <measure>Full blood count</measure>
    <time_frame>Baseline and 10 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Parental education</measure>
    <time_frame>Baseline</time_frame>
    <description>Determined by highest educational grade as measured with the &quot;Standaard Onderwijsindeling (SOI)&quot; classification by Statistics Netherlands (Centraal Bureau voor Statistiek; CBS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Parental occupation</measure>
    <time_frame>Baseline</time_frame>
    <description>Determined by the most appropriate level of education for the particular occupation</description>
  </other_outcome>
  <other_outcome>
    <measure>Educational level</measure>
    <time_frame>Baseline and 26 weeks</time_frame>
    <description>Determined using the ISCED (International Standard Classification of Education) 2011 levels</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Neurofibromatosis Type 1</condition>
  <arm_group>
    <arm_group_label>Lamotrigine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lamotrigine during 28 consecutive weeks:
8 weeks dose-increase phase: from 25mg once daily to 100mg twice daily
18 weeks target-dose phase: 100mg twice daily
2 weeks decline-phase: 100mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets during 28 consecutive weeks, with identical appearance to lamotrigine tablets, mimicking the lamotrigine dosing schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamotrigine</intervention_name>
    <arm_group_label>Lamotrigine</arm_group_label>
    <other_name>Lamictal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NF1 patients with a genetically confirmed diagnosis

          -  Age 12-17.5 years at inclusion

          -  Oral and written informed consent by parents and assent from participants

        Exclusion Criteria:

          -  Segmental NF1

          -  Severe hearing problems or deafness

          -  Severe visual problems or blindness

          -  Use of the following medication, as of interaction with lamotrigine: phenytoin,
             carbamazepine, phenobarbital, primidon, rifampicin, atazanavir/ritonavir,
             lopinavir/ritonavir, oxcarbazepine, topiramate, oral contraceptive pill including
             stop-week (estrogen and progesterone) and valproic acid during 3 months before
             inclusion.

          -  Use of psycho-active medication other than methylphenidate

          -  Previous allergic reactions to anti-epileptic drugs

          -  Epilepsy or epilepsy in the past

          -  Suicidal thoughts or behaviour

          -  Renal insufficiency

          -  Liver insufficiency

          -  Pregnancy

          -  Brain tumour or other brain pathology potentially influencing the outcome measures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ype Elgersma, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henriette A Moll, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Claire Y de Wit, MD, PhD</last_name>
    <phone>+31107036956</phone>
    <email>m.c.y.dewit@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Myrthe J Ottenhoff, MD, MSc</last_name>
    <phone>+31107036148</phone>
    <email>m.ottenhoff@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Legius, MD, PhD</last_name>
      <phone>+3216345903</phone>
      <email>eric.legius@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Ellen Plasschaert, MSc</last_name>
      <phone>+3216345903</phone>
      <email>ellen.plasschaert@uzleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Ellen Plasschaert, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Legius, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <state>South Holland</state>
        <zip>3015CN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marie-Claire Y de Wit, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Myrthe Ottenhoff, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.erasmusmc.nl/encore/</url>
    <description>ENCORE expertise center</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2014</study_first_submitted>
  <study_first_submitted_qc>October 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2014</study_first_posted>
  <last_update_submitted>June 22, 2017</last_update_submitted>
  <last_update_submitted_qc>June 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>M.J. Ottenhoff, MD</investigator_full_name>
    <investigator_title>MD, MSc</investigator_title>
  </responsible_party>
  <keyword>Neurofibromatosis type 1</keyword>
  <keyword>NF1</keyword>
  <keyword>Cognition</keyword>
  <keyword>Learning problems</keyword>
  <keyword>Lamotrigine</keyword>
  <keyword>Transcranial magnetic stimulation</keyword>
  <keyword>TMS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurofibromatosis 1</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

